Matinas BioPharma Holdings, Inc. (MTNB) Net margin 2016–2024
Matinas BioPharma Holdings, Inc. (MTNB) net profit margin by fiscal year — reported net income divided by reported revenue.
-2212.7%FY2024 · since FY2016: -3906.9% → -2212.7%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2024 | -2212.7% | -1493.0 pp |
| FY2023 | -719.6% | +62907.6 pp |
| FY2022 | -63627.3% | -48922.2 pp |
| FY2021 | -14705.1% | +10288.1 pp |
| FY2020 | -24993.1% | -10485.7 pp |
| FY2019 | -14507.4% | -5099.1 pp |
| FY2018 | -9408.3% | — |
| FY2016 | -3906.9% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice